Talphera Inc

CEO’s $0.59 buy of 800k Talphera shares shows bullish outlook amid upcoming nafamostat data—investors gauge short‑term upside and risk.

CEO insider buys 213k Talphera shares at $0.59, signaling short‑term confidence and a potential stabilizing effect on the stock’s price.

Talphera’s latest insider buying and pre‑funded warrants signal a bullish view on its acute‑pain pipeline, hinting at future upside above $1.00.